AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IBRX · NASDAQ · Biotechnology

ImmunityBio (IBRX)

Commercializes ANKTIVA while developing cytokine, NK-cell, and vaccine immunotherapies for cancer.

$8.67

vs last close−0.62 (−6.71%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	0	0	0	1	6	8	17	26	32	38	44	51
Cost of revenue	0	0	0	0	0	0	0	0	4	4	0	0
Gross profit	0	0	0	1	6	8	16	26	28	34	44	51
	80	86	95	100	86	77	81	98	84	99	114	113
Research & development	48	52	53	51	50	35	48	55	51	61	65	58
Selling, general & administrative	32	33	42	49	36	42	33	42	33	38	44	51
Other expenses	0	1	0	0	0	0	0	0	0	0	5	4
Operating income	−80	−85	−95	−99	−80	−69	−64	−71	−56	−65	−70	−62
	−16	−148	−39	−35	−5	10	−65	−21	−12	3	−563	−169
Interest income	1	2	2	1	1	1	1	1	2	3	2	3
Interest expense	35	32	37	39	40	15	29	29	28	27	28	0
Other non-operating income	−20	116	7	−4	−35	−25	37	−8	−16	−30	535	169
Income before tax	−96	−233	−134	−135	−86	−59	−130	−92	−67	−62	−633	−230
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−96	−233	−134	−135	−86	−59	−130	−93	−67	−62	−633	−230
Net income	−96	−233	−134	−135	−86	−59	−130	−93	−67	−62	−633	−230
EPS, basic	−$0.19	−$0.40	−$0.20	−$0.20	−$0.12	−$0.08	−$0.15	−$0.10	−$0.07	−$0.06	−$0.62	−$0.22
EPS, diluted	−$0.19	−$0.40	−$0.20	−$0.20	−$0.12	−$0.09	−$0.15	−$0.10	−$0.07	−$0.06	−$0.62	−$0.22
Weighted average shares, basic	498	591	673	687	696	733	853	888	947	990	1,027	1,050
Weighted average shares, diluted	498	591	673	687	698	735	853	888	947	990	1,027	1,050
EBITDA	−56	−197	−98	−91	−41	−40	−97	−60	−36	−31	−600	−222
Depreciation & amortization	5	5	5	4	4	4	4	4	4	4	4	9
EBIT	−61	−201	−102	−96	−46	−44	−101	−63	−40	−35	−604	−230